Stryker Co. (NYSE:SYK) insider Timothy J. Scannell sold 5,282 shares of the company’s stock in a transaction dated Wednesday, January 16th. The stock was sold at an average price of $163.50, for a total transaction of $863,607.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Timothy J. Scannell also recently made the following trade(s):

  • On Tuesday, December 18th, Timothy J. Scannell sold 9,332 shares of Stryker stock. The stock was sold at an average price of $161.60, for a total transaction of $1,508,051.20.

Shares of SYK traded up $1.01 during trading hours on Thursday, reaching $164.41. The company’s stock had a trading volume of 1,164,182 shares, compared to its average volume of 1,525,382. The company has a market capitalization of $60.67 billion, a price-to-earnings ratio of 25.33, a P/E/G ratio of 2.02 and a beta of 0.76. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $179.84. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.01. The company had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.26 billion. Stryker had a return on equity of 28.00% and a net margin of 9.31%. Equities research analysts expect that Stryker Co. will post 7.28 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 31st. Stockholders of record on Monday, December 31st will be issued a $0.52 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.47. The ex-dividend date is Friday, December 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.27%. Stryker’s dividend payout ratio is currently 32.05%.

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC grew its holdings in shares of Stryker by 24.0% during the second quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock worth $899,662,000 after buying an additional 1,032,333 shares in the last quarter. Macquarie Group Ltd. grew its holdings in shares of Stryker by 4.8% during the second quarter. Macquarie Group Ltd. now owns 114,822 shares of the medical technology company’s stock worth $19,389,000 after buying an additional 5,207 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Stryker during the second quarter worth about $3,031,000. Centaurus Financial Inc. purchased a new stake in shares of Stryker during the second quarter worth about $110,000. Finally, Moneta Group Investment Advisors LLC boosted its position in shares of Stryker by 354,407.4% in the second quarter. Moneta Group Investment Advisors LLC now owns 95,717 shares of the medical technology company’s stock worth $135,000 after acquiring an additional 95,690 shares during the last quarter. Institutional investors own 73.31% of the company’s stock.

SYK has been the subject of a number of research analyst reports. Oppenheimer set a $170.00 price target on shares of Stryker and gave the company a “hold” rating in a report on Friday, November 9th. Citigroup cut their price target on shares of Stryker from $174.00 to $169.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research reissued a “hold” rating and issued a $162.00 price target on shares of Stryker in a report on Monday, December 31st. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, November 27th. They issued a “neutral” rating and a $180.00 price target for the company. Finally, Evercore ISI upgraded Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 price objective on the stock in a report on Wednesday, January 2nd. Eight investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Stryker presently has an average rating of “Buy” and an average target price of $181.68.

COPYRIGHT VIOLATION WARNING: “Stryker Co. (SYK) Insider Timothy J. Scannell Sells 5,282 Shares” was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.watchlistnews.com/stryker-co-syk-insider-timothy-j-scannell-sells-5282-shares/2753593.html.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: What is intrinsic value?

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.